Author pages are created from data sourced from our academic publisher partnerships and public sources.
- Publications
- Influence
Discriminating functional and non‐functional p53 in human tumours by p53 and MDM2 immunohistochemistry
- R. Nenutil, J. Šmardová, +9 authors B. Vojtesek
- Biology, Medicine
- The Journal of pathology
- 1 November 2005
Mutation and/or loss of the TP53 tumour suppressor gene is the single most common genetic abnormality in human cancer. The majority of TP53 mutations lead to stabilization of the protein, so that… Expand
Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies.
- J. Bartek, J. Bártková, +7 authors D. Lane
- Biology, Medicine
- Oncogene
- 1 September 1991
Accumulation of the p53 protein was analysed in 212 human malignant lesions. Immunohistochemical staining with new polyclonal (CM-1) and monoclonal antibodies (BP 53-12 and BP53-24) to p53 on… Expand
Increased accumulation of p53 protein in cisplatin‐resistant ovarian cell lines
- R. Brown, C. Clugston, +4 authors B. Vojtesek
- Biology, Medicine
- International journal of cancer
- 21 October 1993
We have examined p53 protein levels in cell lines selected for resistance to the chemotherapeutic drug cis‐diamminedichloroplatinum (II), cisplatin. The majority of the independent… Expand
C-terminal phosphorylation of Hsp70 and Hsp90 regulates alternate binding to co-chaperones CHIP and HOP to determine cellular protein folding/degradation balances
- P. Muller, E. Růčková, +4 authors B. Vojtesek
- Biology, Medicine
- Oncogene
- 20 June 2013
Heat shock proteins Hsp90 and Hsp70 facilitate protein folding but can also direct proteins for ubiquitin-mediated degradation. The mechanisms regulating these opposite activities involve Hsp binding… Expand
Immunochemical analysis of the interaction of p53 with MDM2;--fine mapping of the MDM2 binding site on p53 using synthetic peptides.
- S. Picksley, B. Vojtesek, A. Sparks, D. Lane
- Biology, Medicine
- Oncogene
- 1 September 1994
The function of p53 is modulated by binding to a number of cellular and viral proteins, such as MDM2 and SV40 large T antigen. An initial immunochemical characterization of the p53-MDM2 complex in a… Expand
Chaperone-dependent stabilization and degradation of p53 mutants
- P. Muller, R. Hrstka, D. Coomber, D. Lane, B. Vojtesek
- Medicine, Biology
- Oncogene
- 29 May 2008
p53 missense mutant proteins commonly show increased stability compared to wild-type p53, which is thought to depend largely on the inability of mutant p53 to induce the ubiquitin ligase MDM2.… Expand
Emerging roles for the pro-oncogenic anterior gradient-2 in cancer development
- E. Chevet, D. Fessart, +6 authors T. Hupp
- Medicine, Biology
- Oncogene
- 16 May 2013
Clinical studies have defined the core ‘genetic blueprint’ of a cancer cell, but this information does not necessarily predict the cancer phenotype. Signalling hubs that mediate such phenotype have… Expand
Detection of the p53 response in zebrafish embryos using new monoclonal antibodies
The zebrafish has many advantages as a vertebrate model organism and has been extensively used in the studies of development. Its potential as a model in which to study tumour suppressor and oncogene… Expand
Anterior gradient 2: a novel player in tumor cell biology.
- V. Brychtová, B. Vojtesek, R. Hrstka
- Medicine, Biology
- Cancer letters
- 1 May 2011
AGR2 has evolutionarily conserved roles in development and tissue regeneration and is linked with several human cancers. The exact functions and regulation of AGR2 are poorly understood, but current… Expand
Patterns of expression of the p53 tumour suppressor in human breast tissues and tumours in situ and in vitro
- J. Bartek, J. Bártková, +4 authors D. Lane
- Biology, Medicine
- International journal of cancer
- 15 November 1990
An extensive series of histological sections reflecting the various states of normal breast tissue, and a range of benign and malignant lesions, were examined for the expression of the p53 protein… Expand